Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00865228 | Jul → Nov 2007 | hyperlipoproteinemia | Takeda | Terminated | No outcome recorded |
| Phase 2 | NCT00813527 | Feb 2006 → Jan 2007 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00864643 | Sep 2004 → Feb 2005 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT00532558 | Oct 2007 → May 2008 | hyperlipidemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00532311 | Jul 2007 → Apr 2008 | hyperlipidemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00286481 | Mar 2006 → May 2007 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00868127 | Dec 2005 → Jul 2007 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00249899 | Nov 2005 → Mar 2007 | hyperlipoproteinemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00263081 | Nov 2005 → Mar 2007 | hyperlipidemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00256178 | Oct 2005 → Mar 2007 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00249912 | Oct 2005 → Apr 2007 | hyperlipoproteinemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00251680 | Oct 2005 → May 2007 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00268697 | Oct 2005 → Jan 2007 | hyperlipoproteinemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00143663 | Sep 2005 → Apr 2006 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00143676 | Aug 2005 → Aug 2006 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00487994 | Nov 2004 → May 2007 | hyperlipidemia | Takeda | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lapaquistat acetate | “TAK-475 (lapaquistat acetate) is a squalene synthase inhibitor currently under development at Takeda for the treatment of dyslipidemia.” NCT00268697 ↗10“TGRD is developing an orally active squalene synthase inhibitor, TAK-475 (lapaquistat acetate) for the treatment of dyslipidemia.” NCT00143676 ↗ “Lapaquistat acetate is a squalene synthase inhibitor currently under development at Takeda for the treatment of dyslipidemia.” NCT00256178 ↗ “BACKGROUND: Lapaquistat acetate is a squalene synthase inhibitor investigated for the treatment of hypercholesterolemia.” PMID 21518985 ↗ Apr 2011 “Lapaquistat acetate inhibits the biosynthesis of cholesterol by inhibiting the enzyme squalene synthase” NCT00263081 ↗ “Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.” NCT00532311 ↗ “Lapaquistat acetate is being developed by Takeda for the treatment of hypercholesterolemia.” NCT00865228 ↗ |
| Known as | Lapaquistat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00487994 ↗ |
| Known as | TAK 475 | ChEMBL registry synonym — accepted as the source's own label CHEMBL435224 ↗ |
| Action | Inhibit | “Lapaquistat acetate is a squalene synthase inhibitor investigated for the treatment of hypercholesterolemia.” PMID 21518985 ↗ Apr 20111“Squalene synthetase inhibitor” CHEMBL435224 ↗ |
| Modality | Small molecule | — CHEMBL435224 ↗ |
| Route | Oral | “Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks” NCT00143663 ↗ |
| Target | FDFT1 | “Squalene synthetase inhibitor” CHEMBL435224 ↗ |